[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343145-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343145-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","n6-methyladenosine-m6a-rna-modification-in-chronic-myeloid-leukemia-unveiling-a-novel-therapeutic-target","N6-methyladenosine (m6A) RNA modification in chronic myeloid leukemia - unveiling a novel therapeutic target","","N6-methyladenosine (m6A) is the most prevalent internal mRNA modification, governing gene expression by shaping RNA metabolism across multiple stages. Growing evidence links aberrant m6A regulation to both oncogenic and suppressive outcomes, including hematological malignancies. This review examines m6A biology in chronic myeloid leukemia (CML) driven by the BCR-ABL1 fusion, highlighting effects on leukemic cell survival and drug resistance. It discusses methylation control by writers, erasers, and readers, and evaluates therapeutic promise of inhibitors targeting m6A regulators.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/n6-methyladenosine-m6a-rna-modification-in-chronic-myeloid-leukemia-unveiling-a-novel-therapeutic-target/343145/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/n6-methyladenosine-m6a-rna-modification-in-chronic-myeloid-leukemia-unveiling-a-novel-therapeutic-target/343145.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is m6A and why is it important for gene regulation?","Question",{"text":63,"@type":64},"m6A is the most prevalent internal mRNA modification. It regulates gene expression by modulating RNA metabolism at multiple stages.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is m6A regulated at the molecular level?",{"text":68,"@type":64},"m6A regulation depends on writers (methyltransferases), erasers (demethylases), and readers that recognize specific m6A marks. Modulation can be difficult because precise control may be needed globally or at specific sites.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is m6A relevant to chronic myeloid leukemia and potential therapy?",{"text":72,"@type":64},"The review focuses on m6A’s role in CML, emphasizing impacts on leukemia cell survival and mechanisms of drug resistance. It also notes that inhibitors targeting m6A regulators show promise in preclinical models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343145,1790193271,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Cellular and Molecular Life Sciences (2024) 81:326  \n[https://doi.org/10.1007/s00018-024-05379-w](https://doi.org/10.1007/s00018-024-05379-w) Cellular and Molecular Life Sciences  \nN6‑methyladenosine (m6A) RNA modification in chronic myeloid leukemia: unveiling a novel therapeutic target  \nGuillermo Fernandez Rodriguez1 · Marco Tarullo1 · Alessandro Fatica1  \nReceived: 28 May 2024 / Revised: 2 July 2024 / Accepted: 22 July 2024 © The Author(s) 2024  \nAbstract  \nN6-methyladenosine (m6A), the most prevalent internal mRNA modification, plays a critical role in physiological processes by regulating gene expression through modulation of mRNA metabolism at multiple stages. In recent years, m6A has garnered significant attention for a deeper understanding of the initiation, progression, and drug resistance of various cancers, including hematological malignancies. Dysregulation of m6A has been implicated in both cancer promotion and suppression. m6Amethylation is a complex regulatory process involving methyltransferases (writers), demethylases (erasers), and proteins that recognize specific m6A modifications (readers) . This intricate interplay presents challenges for precisely modulating m6A levels, either globally or at specific sites. This review specifically focuses on the role of m6A in chronic myeloid leukemia (CML), a blood cancer characterized by the BCR-ABL1 fusion. We emphasize its impact on leukemia cell survival and drug resistance mechanisms. Notably, inhibitors targeting m6A regulators show promise in preclinical models, suggesting a potential therapeutic avenue for CML. Integrating our understanding of m6A biology with current treatment strategies may lead to more effective therapies, especially for patients with advanced-stage or resistant CML.  \nKeywords m6A · CML · Epitranscriptomics · Cancer  \nIntroduction  \nm6A is the most abundant internal modification of messenger RNAs (mRNAs) and long non-coding RNAs (lncRNAs)(reviewed in [1]) . Despite its initial discovery in 1974, the field of m6A biology remained largely unexplored for decades until the development of sequencing methods for mapping m6A modification in RNA species [2, 3] . However, quantifying m6A abundance at specific positions within individual transcripts remains a significant challenge, despite the development of numerous methodologies for mapping m6A distribution [4–7] . Currently, it is undoubtedly the most extensively studied RNA modification with the greatest therapeutic potential. Methylation at the N6 position of the target adenosine residue in RNA occurs co-transcriptionally  \nGuillermo Fernandez Rodriguez and Marco Tarullo contributed equally.  \n* Alessandro Fatica [alessandro.fatica@uniroma1.it](alessandro.fatica@uniroma1.it)  \n1 Department of Biology and Biotechnologies “Charles Darwin”, Sapienza University of Rome, 00185 Rome, Italy  \nby the methyltransferase complex composed of methyltransferase-like protein 3 (METTL3, also known as MT-A70) and methyltransferase-like protein 14 (METTL14) (Fig. 1)(reviewed in [8]) . Although METTL14 lacks catalytic activity itself, it plays a crucial role in recognizing the DRACH sequence (D = A, G, or U; R = A or G; H = A, C, or U; A methylated adenosine) in RNA, facilitating methylation of the adenosine within this motif by the catalytic subunit, METTL3 . This complex is further regulated by a multiprotein assembly including Wilms tumor 1-associated protein (WTAP), Vir-like m6A methyltransferase-associated (VIRMA, also known as KIAA1429), Cbl proto-oncogene like 1 (CBLL1), RNA-binding motif 15 (RBM15), and zinc finger CCCH-type containing 13 (ZC3H13) [8] . m6A is not randomly distributed, but rather targeted to specific regions within RNA molecules [8] . These enriched regions often occur near the stop codon, within the 3' untranslated region (3'UTR), or in particularly long exons. Furthermore, it has also been found in intronic regions of pre-mRNAs and long noncoding RNAs [8] . Several factors influence the ","cbCairPAVjDD7pxQ","https://ap.wps.com/l/cbCairPAVjDD7pxQ","pdf",1852990,13,"English","# Abstract\n# Introduction\n## m6A writers and erasers\n## Readers and targeting mechanisms\n## m6A in chronic myeloid leukemia","[{\"question\":\"What is m6A and why is it important for gene regulation?\",\"answer\":\"m6A is the most prevalent internal mRNA modification. It regulates gene expression by modulating RNA metabolism at multiple stages.\"},{\"question\":\"How is m6A regulated at the molecular level?\",\"answer\":\"m6A regulation depends on writers (methyltransferases), erasers (demethylases), and readers that recognize specific m6A marks. Modulation can be difficult because precise control may be needed globally or at specific sites.\"},{\"question\":\"Why is m6A relevant to chronic myeloid leukemia and potential therapy?\",\"answer\":\"The review focuses on m6A’s role in CML, emphasizing impacts on leukemia cell survival and mechanisms of drug resistance. It also notes that inhibitors targeting m6A regulators show promise in preclinical models.\"}]","N6-methyladenosine (m6A) RNA modification in chronic myeloid leukemia - unveiling a novel therapeutic target | PDF",1790050083,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/334ae1480b28f40c0b5534c1ce14a54f.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df0046b86194708143ee51c9ed71eb2f.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce287f6ab6e81f802b94949d1c52d5e4.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7df599f49c1f82a586d1adbb030d88a.webp",980,1301]